Literature DB >> 32354386

Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar.

Javier Díez1, Arantxa González2, Jason C Kovacic3.   

Abstract

Myocardial interstitial fibrosis (MIF) is a histological hallmark of several cardiac diseases that alter myocardial architecture and function and are associated with progression to heart failure. MIF is a diffuse and patchy process, appearing as a combination of interstitial microscars, perivascular collagen fiber deposition, and increased thickness of mysial collagen strands. Although MIF arises mainly because of alterations in fibrillar collagen turnover leading to collagen fiber accumulation, there are also alterations in other nonfibrillar extracellular matrix components, such as fibronectin and matricellular proteins. Furthermore, in addition to an excess of collagen, qualitative changes in collagen fibers also contribute to the detrimental impact of MIF. In this part 3 of a 4-part JACC Focus Seminar, we review the evidence on the complex mechanisms leading to MIF, as well as its contribution to systolic and diastolic cardiac dysfunction and impaired clinical outcomes in patients with nonischemic heart disease.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biomarker; collagen; fibroblast; heart failure; myocardial interstitial fibrosis

Mesh:

Substances:

Year:  2020        PMID: 32354386      PMCID: PMC7213023          DOI: 10.1016/j.jacc.2020.03.019

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  122 in total

Review 1.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

2.  Computer-assisted quantitation of myocardial fibrosis in histologic sections.

Authors:  R H Hoyt; E Ericksen; S M Collins; D J Skorton
Journal:  Arch Pathol Lab Med       Date:  1984-04       Impact factor: 5.534

3.  Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness.

Authors:  Inês Falcão-Pires; Nazha Hamdani; Attila Borbély; Cristina Gavina; Casper G Schalkwijk; Jolanda van der Velden; Loek van Heerebeek; Ger J M Stienen; Hans W M Niessen; Adelino F Leite-Moreira; Walter J Paulus
Journal:  Circulation       Date:  2011-08-15       Impact factor: 29.690

4.  Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction.

Authors:  Mario Kasner; Dirk Westermann; Begoña Lopez; Regina Gaub; Felicitas Escher; Uwe Kühl; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  J Am Coll Cardiol       Date:  2011-02-22       Impact factor: 24.094

5.  Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy.

Authors:  Paola Melacini; Cristina Basso; Annalisa Angelini; Chiara Calore; Fabiana Bobbo; Barbara Tokajuk; Nicoletta Bellini; Gessica Smaniotto; Mauro Zucchetto; Sabino Iliceto; Gaetano Thiene; Barry J Maron
Journal:  Eur Heart J       Date:  2010-05-31       Impact factor: 29.983

6.  Normalization of diastolic dysfunction in aortic stenosis late after valve replacement.

Authors:  B Villari; G Vassalli; E S Monrad; M Chiariello; M Turina; O M Hess
Journal:  Circulation       Date:  1995-05-01       Impact factor: 29.690

7.  Fibroblast-specific TGF-β-Smad2/3 signaling underlies cardiac fibrosis.

Authors:  Hadi Khalil; Onur Kanisicak; Vikram Prasad; Robert N Correll; Xing Fu; Tobias Schips; Ronald J Vagnozzi; Ruijie Liu; Thanh Huynh; Se-Jin Lee; Jason Karch; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2017-09-11       Impact factor: 14.808

8.  Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).

Authors:  Daniel R Messroghli; James C Moon; Vanessa M Ferreira; Lars Grosse-Wortmann; Taigang He; Peter Kellman; Julia Mascherbauer; Reza Nezafat; Michael Salerno; Erik B Schelbert; Andrew J Taylor; Richard Thompson; Martin Ugander; Ruud B van Heeswijk; Matthias G Friedrich
Journal:  J Cardiovasc Magn Reson       Date:  2017-10-09       Impact factor: 5.364

Review 9.  Myocardial fibrosis: biomedical research from bench to bedside.

Authors:  Mariann Gyöngyösi; Johannes Winkler; Isbaal Ramos; Quoc-Tuan Do; Hüseyin Firat; Kenneth McDonald; Arantxa González; Thomas Thum; Javier Díez; Frédéric Jaisser; Anne Pizard; Faiez Zannad
Journal:  Eur J Heart Fail       Date:  2017-02       Impact factor: 15.534

10.  Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome.

Authors:  Erik B Schelbert; Yaron Fridman; Timothy C Wong; Hussein Abu Daya; Kayla M Piehler; Ajay Kadakkal; Christopher A Miller; Martin Ugander; Maren Maanja; Peter Kellman; Dipan J Shah; Kaleab Z Abebe; Marc A Simon; Giovanni Quarta; Michele Senni; Javed Butler; Javier Diez; Margaret M Redfield; Mihai Gheorghiade
Journal:  JAMA Cardiol       Date:  2017-09-01       Impact factor: 14.676

View more
  9 in total

1.  Angiotensin-(3-7) alleviates isoprenaline-induced cardiac remodeling via attenuating cAMP-PKA and PI3K/Akt signaling pathways.

Authors:  Yonglin Zhang; Zhenglu Shang; Aijun Liu
Journal:  Amino Acids       Date:  2021-09-07       Impact factor: 3.520

2.  Prognostic Value of Late Enhanced Cardiac Magnetic Resonance Imaging Derived Texture Features in Dilated Cardiomyopathy Patients With Severely Reduced Ejection Fractions.

Authors:  Shenglei Shu; Cheng Wang; Ziming Hong; Xiaoyue Zhou; Tianjng Zhang; Qinmu Peng; Jing Wang; Chuansheng Zheng
Journal:  Front Cardiovasc Med       Date:  2021-12-17

Review 3.  Cardiac consequences of intermittent hypoxia: a matter of dose? A systematic review and meta-analysis in rodents.

Authors:  Elise Belaidi; Charles Khouri; Olfa Harki; Sébastien Baillieul; Gilles Faury; Anne Briançon-Marjollet; Jean-Louis Pépin; Claire Arnaud
Journal:  Eur Respir Rev       Date:  2022-04-13

Review 4.  Treatment of myocardial interstitial fibrosis in pathological myocardial hypertrophy.

Authors:  Fuyu Zhu; Peng Li; Yanhui Sheng
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

Review 5.  Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches.

Authors:  Begoña López; Susana Ravassa; María U Moreno; Gorka San José; Javier Beaumont; Arantxa González; Javier Díez
Journal:  Nat Rev Cardiol       Date:  2021-02-10       Impact factor: 32.419

6.  IGF-1 protects against angiotensin II-induced cardiac fibrosis by targeting αSMA.

Authors:  Sangmi Ock; Woojin Ham; Chae Won Kang; Hyun Kang; Wang Soo Lee; Jaetaek Kim
Journal:  Cell Death Dis       Date:  2021-07-09       Impact factor: 8.469

Review 7.  Immune Cells and Immunotherapy for Cardiac Injury and Repair.

Authors:  Joel G Rurik; Haig Aghajanian; Jonathan A Epstein
Journal:  Circ Res       Date:  2021-05-27       Impact factor: 23.213

8.  Creating a Natural Vascular Scaffold by Photochemical Treatment of the Extracellular Matrix for Vascular Applications.

Authors:  Katalin Kauser; Kevin S Warner; Blake Anderson; Edgar Dalles Keyes; R B Hayes; Eric Kawamoto; D H Perkins; Robert Scott; Jim Isaacson; Barb Haberer; Ann Spaans; Ronald Utecht; Hank Hauser; Andrew George Roberts; Myles Greenberg
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

Review 9.  Cell therapy in patients with heart failure: a comprehensive review and emerging concepts.

Authors:  Roberto Bolli; Mitesh Solankhi; Xiang-Liang Tang; Arunpreet Kahlon
Journal:  Cardiovasc Res       Date:  2022-03-16       Impact factor: 10.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.